A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
This study is to evaluate the safety, biodistribution, radiation dosimetry and tumor uptake of the \[68Ga\]/ \[131I\]-IR199 in patients with Claudin 18.2 positive gastric cancer and pancreatic cancer.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Informed consent must be obtained in writing from the subject, their legally authorized representative, or caregiver.
• Age equal to or above 18 years old.
• Histologically or cytologically confirmed gastric cancer or pancreatic cancer with Claudin 18.2 expression.
• Must have ≥1 Claudin 18.2 positive lesions.
Locations
Other Locations
China
Huashan Hospital
RECRUITING
Shanghai
Contact Information
Primary
Yihui Guan, MD
guanyihui@hotmail.com
+86 13764308300
Time Frame
Start Date: 2026-06-01
Estimated Completion Date: 2027-05-31
Participants
Target number of participants: 10
Treatments
Experimental: [68Ga]/ [131I]-IR199, single dose
\[68Ga\]/ \[131I\]-IR199, single dose
Related Therapeutic Areas
Sponsors
Leads: Huashan Hospital